117 related articles for article (PubMed ID: 12860588)
1. The use of statins in conjunction with protease inhibitors and in renal insufficiency.
Mikhail N; Cope D
Arch Intern Med; 2003 Jul; 163(13):1615-6; author reply 1616. PubMed ID: 12860588
[No Abstract] [Full Text] [Related]
2. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
3. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
4. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
Launay-Vacher V; Izzedine H; Deray G
Int J Cardiol; 2005 May; 101(1):9-17. PubMed ID: 15860377
[TBL] [Abstract][Full Text] [Related]
5. Risk for myopathy with statin therapy in high-risk patients.
Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
[TBL] [Abstract][Full Text] [Related]
6. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Corsini A; Holdaas H
Ren Fail; 2005; 27(3):259-73. PubMed ID: 15957541
[TBL] [Abstract][Full Text] [Related]
8. Possible differences between fibrates in pharmacokinetic interactions with statins.
Ballantyne CM; Davidson MH
Arch Intern Med; 2003 Oct; 163(19):2394-5. PubMed ID: 14581261
[No Abstract] [Full Text] [Related]
9. [Statins and their pleiotropic effects].
Galus R; Zandecki Ł; Jóźwiak J; Włodarski K
Pol Merkur Lekarski; 2008 Jun; 24(144):545-8. PubMed ID: 18702340
[TBL] [Abstract][Full Text] [Related]
10. Statins and renal function. Is the compound and dose making a difference?
Athyros VG; Karagiannis A; Kakafika A; Elisaf M; Mikhailidis DP
Nephrol Dial Transplant; 2007 Mar; 22(3):963-4; author reply 964. PubMed ID: 17255130
[No Abstract] [Full Text] [Related]
11. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease.
Afzali B; Haydar AA; Vinen K; Goldsmith DJ
J Am Soc Nephrol; 2004 Aug; 15(8):2161-8. PubMed ID: 15284301
[No Abstract] [Full Text] [Related]
12. Summary of the role of statins in the treatment of dyslipidemia.
Carr LL
J Am Osteopath Assoc; 2003 Jul; 103(7 Suppl 3):S1-3. PubMed ID: 12884937
[No Abstract] [Full Text] [Related]
13. Pitavastatin (Livalo)--the seventh statin.
Med Lett Drugs Ther; 2010 Jul; 52(1343):57-8. PubMed ID: 20651638
[No Abstract] [Full Text] [Related]
14. [Statins in chronic renal disease].
Ferreira SR; Rocha AM; Saraiva JF
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic implications of HMG CoA reductase inhibitors.
White CM
Conn Med; 2000 Sep; 64(9):533-5. PubMed ID: 11055086
[No Abstract] [Full Text] [Related]
16. Statins for high-risk patients without heart disease or high cholesterol.
Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
[No Abstract] [Full Text] [Related]
17. [Statins in patients with renal failure--the current therapeutic status].
Filipiak KJ; Zawadzka-Byśko M
Przegl Lek; 2005; 62 Suppl 2():51-4. PubMed ID: 16623120
[TBL] [Abstract][Full Text] [Related]
18. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information.
Mück W
Br J Clin Pharmacol; 2000 Jan; 49(1):87-90. PubMed ID: 10691326
[No Abstract] [Full Text] [Related]
19. Beneficial effects of statins on the kidney: the evidence moves from mouse to man.
Afzali B; Haydar AA; Vinen K; Goldsmith DJ
Nephrol Dial Transplant; 2004 May; 19(5):1032-6. PubMed ID: 14993488
[No Abstract] [Full Text] [Related]
20. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
